We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One cancer drug, two diabetes drugs and two next-generation blood thinners topped the Medicare Part D charts for 2017—all with sales of more than $2.5 billion apiece. But two other numbers stood out at the top of the list: the 15%-plus price increases for